A single sublingual dose of an adenovirus-based vaccine protects against lethal Ebola challenge in mice and guinea pigs.

Authors:
Address: Division of Pharmaceutics, College of Pharmacy, The University of Texas at Austin, Austin, Texas 78712, United States.
Journal:

Publication:

abstract

sublingual (SL) delivery, a noninvasive immunization method that bypasses the intestinal tract for direct entry into the circulation, was evaluated with an adenovirus (Ad5)-based vaccine for Ebola. mice and guinea pigs were immunized via the intramuscular (IM), nasal (IN), oral (PO) and SL routes. SL immunization elicited strong transgene expression in and attracted CD11c(+) antigen presenting cells to the mucosa. A SL dose of 1 × 10⁸ infectious particles induced Ebola Zaire glycoprotein (ZGP)-specific IFN-γ⁺ T cells in spleen, bronchoalveolar lavage, mesenteric lymph nodes and submandibular lymph nodes (SMLN) of naive mice in a manner similar to the same dose given IN. Ex vivo CFSE and in vivo cytotoxic T lymphocyte (CTL) assays confirmed that SL immunization elicits a notable population of effector memory CD8+ T cells and strong CTL responses in spleen and SMLN. SL immunization induced significant ZGP-specific Th1 and Th2 type responses unaffected by pre-existing immunity (PEI) that protected mice and guinea pigs from lethal challenge. SL delivery protected more mice with PEI to Ad5 than IM injection. SL immunization also reduced systemic anti-Ad5 T and B cell responses in naive mice and those with PEI, suggesting that secondary immunizations could be highly effective for both populations.

Related Articles
Nasal delivery of an adenovirus-based vaccine bypasses pre-existing immunity to the vaccine carrier and improves the immune response in mice.
PLoS One. 2008
Nasal delivery of an adenovirus-based vaccine bypasses pre-existing immunity to the vaccine carrier and improves the immune response in mice.
Croyle MA, Patel A, Tran KN, Gray M, Zhang Y, Strong JE, Feldmann H, Kobinger GP. PLoS One. 2008; 3(10):e3548. Epub 2008 Oct 29.
Impact of systemic or mucosal immunity to adenovirus on Ad-based Ebola virus vaccine efficacy in guinea pigs.
J Infect Dis. 2011
Impact of systemic or mucosal immunity to adenovirus on Ad-based Ebola virus vaccine efficacy in guinea pigs.
Richardson JS, Abou MC, Tran KN, Kumar A, Sahai BM, Kobinger GP. J Infect Dis. 2011 Nov; 204 Suppl 3:S1032-42.
Chimpanzee adenovirus vaccine protects against Zaire Ebola virus.
Virology. 2006
Chimpanzee adenovirus vaccine protects against Zaire Ebola virus.
Kobinger GP, Feldmann H, Zhi Y, Schumer G, Gao G, Feldmann F, Jones S, Wilson JM. Virology. 2006 Mar 15; 346(2):394-401. Epub 2005 Dec 13.
Review Recent advances in Ebolavirus vaccine development.
Hum Vaccin. 2010
Review Recent advances in Ebolavirus vaccine development.
Richardson JS, Dekker JD, Croyle MA, Kobinger GP. Hum Vaccin. 2010 Jun; 6(6):439-49. Epub 2010 Jun 1.
Review [Novel vaccines against M. tuberculosis].
Kekkaku. 2006
Review [Novel vaccines against M. tuberculosis].
Okada M. Kekkaku. 2006 Dec; 81(12):745-51.

To top • Home

TraveldoctorOnline 2001 • Disclaimer • webmaster

The contents within traveldoctoronline are presented only for informational purposes and cannot substitute for professional health care or any other medical treatment.All users of this website with health problems should be oblige always to consult their medical doctor before starting any treatment.